Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex and Blarcamesine Are Validated

...falconer -care to comment on this recent great article george posted this morning ??? TIA

First, the paper appeared recently in the journal CNS Drugs. It's not a journal that in my areas of biological expertise (ecology and physiology of certain wild plants) I ever encounter. So, I downloaded a complete copy of the paper and read it through.
https://link.springer.com/content/pdf/10.1007/s40263-023-01007-6.pdf?pdf=button

About itself, the journal makes this claim:

CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.

https://www.springer.com/journal/40263

With the journal's claim of information relevance for both researchers and medical professionals, the paper would seem to be valid. In reading the article's 42 pages of dense text this contention was validated. Simply, professionals who haven't yet read and pondered the paper are not likely to be otherwise up to date on sigma-1 receptor biology, and the drugs (molecules) that can attach to that protein to yield favorable therapeutic outcomes, for a wide variety of central nervous system (CNS) diseases and conditions.

And, yes, in its own section blarcamesine is mentioned 37 times in the paper. Anavex 3-71, in its own section, gets 9 mentions.

The paper has a whopping list of 442 referenced papers, supporting the copious amounts of information in the paper. There is no greater compilation of studies and findings of sigma-1 receptor biology.

So, what do the authors claim for blarcamesine? In section 2.2 the paper lists out and tells of both murine (lab rodent) and human clinical trials of the drug. Simply, the drug is safe (few, and inconsequential side effects) and yields positive therapeutic results for the listed CNS diseases. Nothing that cogent readers of this message board haven't previously learned.

Of course, if ever there were a journal article that should delineate any putative insufficiencies for blarcamesine, this would be it. I found none.

This paper will be closely read by both the researchers and managers of any pharmaceutical company selling or hoping to sell drugs to treat CNS diseases. Very clear. Propitious activation of the sigma-1 receptor protein must now be considered. The science for that is now strong; led primarily by the molecules owned by Anavex Life Sciences Corp.